TEVA completes $3bn refinancing
TEVA Pharmaceuticals, an Israel-based drug company, signed a new $3bn five year unsecured revolving credit facility on Tuesday that replaces its existing smaller loan.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ European securitization issuance database
- ✔ Daily newsletters across markets and asset classes
- ✔ 1 weekly securitization podcast
